Brain neuron‐restricted expression of an FMRP‐independent DGKk enzyme via intra‐cerebral adeno‐associated virus (AAV) gene therapy corrects phosphatidic acid deficiency and rescues disease relevant behavioral phenotypic alterations in a mouse model of Fragile X syndrome (FXS). This evidence concerns the gene DGKK and fragile X syndrome.